Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) CEO Ryan J. Watts sold 29,266 shares of the company's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $591,758.52. Following the completion of the sale, the chief executive officer now owns 260,721 shares of the company's stock, valued at $5,271,778.62. This represents a 10.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Denali Therapeutics Stock Performance
Shares of DNLI traded up $0.07 during trading hours on Wednesday, hitting $21.25. 1,245,656 shares of the stock were exchanged, compared to its average volume of 1,173,671. Denali Therapeutics Inc. has a 12-month low of $14.56 and a 12-month high of $33.33. The company has a market cap of $3.06 billion, a price-to-earnings ratio of -7.70 and a beta of 1.39. The stock's 50-day moving average price is $24.34 and its two-hundred day moving average price is $24.88.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period last year, the firm earned ($0.72) EPS. On average, research analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on DNLI shares. Cantor Fitzgerald lowered shares of Denali Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday, October 7th. Robert W. Baird started coverage on shares of Denali Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $31.00 price target for the company. William Blair assumed coverage on shares of Denali Therapeutics in a research note on Friday, January 3rd. They set an "outperform" rating on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a research note on Tuesday. Finally, Raymond James reaffirmed a "market perform" rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $38.91.
Read Our Latest Analysis on DNLI
Hedge Funds Weigh In On Denali Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MONECO Advisors LLC increased its stake in shares of Denali Therapeutics by 4.6% in the 3rd quarter. MONECO Advisors LLC now owns 9,100 shares of the company's stock worth $265,000 after acquiring an additional 400 shares during the last quarter. Assetmark Inc. grew its holdings in shares of Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company's stock valued at $111,000 after purchasing an additional 580 shares during the period. CWM LLC increased its position in Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company's stock worth $63,000 after purchasing an additional 654 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock worth $152,000 after purchasing an additional 920 shares during the period. Finally, Quest Partners LLC purchased a new position in Denali Therapeutics during the third quarter worth about $73,000. Institutional investors and hedge funds own 92.92% of the company's stock.
Denali Therapeutics Company Profile
(
Get Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
